Mode
Text Size
Log in / Sign up

Berberine reduces weight, lipids in schizophrenia with metabolic syndrome: meta-analysisBerberine may improve weight and cholesterol in schizophrenia patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider berberine as an adjunctive option for metabolic parameters in schizophrenia, but await larger trials.

This meta-analysis of 3 RCTs involving 233 patients with schizophrenia and metabolic syndrome evaluated the effects of adjunctive berberine versus controls. The analysis found that berberine showed superior efficacy over controls in reducing body weight (SMD = -0.56, P = 0.0003), body mass index (SMD = -0.51, P = 0.0001), waist circumference (SMD = -0.31, P = 0.04), total cholesterol (MD = -0.43, P = 0.004), and triglycerides (MD = -0.31, I2 = 0%). Heterogeneity was low for most outcomes except total cholesterol (I2 = 63%).

The authors note that these findings are preliminary and highlight the need for larger, high-quality RCTs to confirm the results. Safety data were not reported, and the certainty of evidence is limited. The practice relevance is that berberine may be a promising intervention for improving certain metabolic parameters in this patient population, but it should not be considered a definitive treatment for metabolic syndrome in schizophrenia.

Clinicians should interpret these results cautiously given the small sample size and lack of long-term follow-up data. Further research is needed to establish the role of berberine in managing metabolic comorbidities in schizophrenia.

How this fits prior evidence

This meta-analysis extends prior coverage of metabolic interventions in schizophrenia by providing pooled evidence for berberine's effects on weight and lipids. It contrasts with the finding that GLP-1R agonists show no causal link to most mental disorders, as berberine targets metabolic parameters directly. It also complements the report on Huanglian Wendan Decoction improving blood pressure and lipids in metabolic syndrome, suggesting another adjunctive option for metabolic abnormalities in psychiatric populations.

Living with schizophrenia often comes with physical health challenges. Many patients also struggle with metabolic syndrome, a group of conditions that include high blood pressure, high blood sugar, and excess body fat. Managing these physical symptoms is vital for long-term health, but finding the right tools to do so can be difficult.

A review of clinical data involving 233 patients suggests that adding berberine to standard care may help. The results showed that those taking berberine saw improvements in several areas compared to a control group. Specifically, the study found reductions in body weight, body mass index (BMI), waist circumference, total cholesterol, and triglycerides.

While these results are promising for managing metabolic health in this specific population, it is important to note that the evidence is still preliminary. Because the data comes from a meta-analysis of smaller trials, larger and higher quality studies are needed to confirm these findings before berberine can be called a standard treatment.

What this means for you:
Berberine shows promise in reducing weight and cholesterol for people with schizophrenia and metabolic syndrome.

Common questions

What specific health markers did berberine improve?

The study found that berberine was more effective than controls in reducing several measurements. These included body weight, body mass index (BMI), waist circumference, total cholesterol, and triglycerides. These results suggest it may help manage the physical symptoms of metabolic syndrome in people with schizophrenia.

Is this a proven treatment for metabolic syndrome?

The evidence is currently considered preliminary. While the data shows promising improvements in weight and cholesterol for patients with schizophrenia, larger and higher quality clinical trials are still needed to confirm these results before it can be used as a standard treatment.

Who was included in this study?

The findings come from an analysis of 233 patients who were diagnosed with both schizophrenia and metabolic syndrome. The study specifically looked at how adding berberine to their routine affected their physical health markers.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Antipsychotic-induced metabolic syndrome complicates the clinical management of schizophrenia. This investigation seeks to examine berberine’s efficacy and safety as adjunctive therapy in schizophrenia patients with metabolic syndrome. A thorough literature search was executed across international (PubMed, Cochrane Library, EMBASE) and Chinese (China National Knowledge Infrastructure, WanFang Data) databases to retrieve randomized controlled trials (RCTs) examining adjunctive berberine for schizophrenia with metabolic syndrome. Data extraction and synthesis were conducted by three independent reviewers employing RevMan 5.3 software. Three eligible RCTs (n = 233) were incorporated. Adjunctive berberine demonstrated superior efficacy over controls in reducing body weight (standardized mean difference (SMD) = −0.56, I² = 0%; P = 0.0003), body mass index (SMD = −0.51, I² = 0%; P = 0.0001), waist circumference (SMD = −0.31, I² = 20%; P = 0.04), total cholesterol (mean difference (MD) = −0.43, I² = 63%; P = 0.004), triglycerides (MD = −0.31, I² = 0%; P  This systematic review provides preliminary evidence supporting adjunctive berberine as a promising intervention for improving certain metabolic parameters in schizophrenia patients with metabolic syndrome. Larger, high-quality RCTs are needed to confirm these observations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.